Neurotoxoplasmosis mimicking intracranial tuberculoma.
Neurotoxoplasmosis is a major cause of morbidity and mortality, especially in immunocompromised patients. Definitive diagnosis is invasive and difficult thereby requiring a therapeutic trial. We herein report a case of an 11-year-old boy who presented with a tuberculoma on computerized tomography (CT) brain and did not show any clinical improvement on anti-tuberculous drugs. Subsequently, reviewing the CT scans and with supportive serology, a diagnosis of neurotoxoplasmosis was considered. A trial of antitoxoplasmosis therapy was given to which the child fully responded in two weeks. Three weeks later, his magnetic resonance imaging showed complete resolution of the lesion. This report provides an insight into the significance of therapeutic trial in neurotoxoplasmosis.
Doraiswamy
V
V
Department of Pediatrics, Seth G.S. Medical College and KEM Hospital, Mumbai, India.
Vaswani
R K
RK
Lahiri
K R
KR
Kondekar
S S
SS
D000981:Antiprotozoal Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D000995:Antitubercular Agents / Q000627:therapeutic use; D001927:Brain Diseases / Q000000981:diagnostic imaging* / Q000188:drug therapy; D003937:Diagnosis, Differential; D015658:HIV Infections / Q000175:diagnosis* / Q000188:drug therapy; D015497:HIV-1; D006801:Humans; D016867:Immunocompromised Host; D008279:Magnetic Resonance Imaging; D008297:Male; D014057:Tomography, X-Ray Computed; D016781:Toxoplasmosis, Cerebral / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000469:parasitology; D016896:Treatment Outcome; D016862:Tuberculoma, Intracranial / Q000000981:diagnostic imaging* / Q000188:drug therapy
D000981:Antiprotozoal Agents; D000995:Antitubercular Agents